About: Evaluation of infliximab as second-line treatment of acute graft versus host disease -validating response on day 7 and 28 as predictors of survival

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Evaluation of infliximab as second-line treatment of acute graft versus host disease -validating response on day 7 and 28 as predictors of survival Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Evaluation of infliximab as second-line treatment of acute graft versus host disease -validating response on day 7 and 28 as predictors of survival
Creator	Andersen, Niels Claus, • Heilmann, • Moser, Ernst Nygaard, Marietta Olesen, Gitte Schjødt, Ida Sengeløv, Henrik
Source	Medline; PMC
abstract	Several immunosuppressive drugs have been proposed for second-line treatment of steroid-refractory acute graft versus host disease (aGvHD) after allogeneic hematopoietic stem cell transplantation. However, the studies on these drugs are small, retrospective, uncontrolled and use different endpoints. Therefore, it remains unknown which treatment is superior. We retrospectively evaluated 68 consecutive patients treated with infliximab for aGvHD. We adhered to recently proposed guidelines for aGvHD trials and thus evaluated response on day 7 and 28. Furthermore, we assessed the composite endpoint 6 months freedom from treatment failure (6MFTF). The majority of patients had grade III-IV aGvHD. We found that 41 patients (60%) responded on day 7 and 31 patients (46%) on day 28. Twenty-four patients (35%) achieved 6MFTF. The main reasons for failure within 6 months were death (n = 31) or additional immunosuppression (n = 16). By six and 24 months, 44 and 34% of the patients were alive respectively. Patients with response to infliximab on day 7 and 28 had significantly higher overall survival (OS) probability than non-responders. We show that response on day 7 and 28 identifies high and low risk groups. Patients who fail to respond should be identified early and offered alternative therapy.
has issue date	2018-02-01(xsd:dateTime)
bibo:doi	10.1038/s41409-018-0099-3
bibo:pmid	29391524
has license	no-cc
sha1sum (hex)	3e768aaea958fcd6f1453fc0ac7ad6e4a982adad
schema:url	https://doi.org/10.1038/s41409-018-0099-3
resource representing a document's title	Evaluation of infliximab as second-line treatment of acute graft versus host disease -validating response on day 7 and 28 as predictors of survival
has PubMed Central identifier	PMC7086567
has PubMed identifier	29391524
schema:publication	Bone Marrow Transplant
resource representing a document's body	covid:3e768aaea958fcd6f1453fc0ac7ad6e4a982adad#body_text
is schema:about of	named entity 'patients' named entity 'acute' named entity 'patients' named entity 'grade' named entity 'graft' named entity 'drugs' named entity 'survival' named entity 'ACUTE GRAFT VERSUS HOST DISEASE' named entity 'IDENTIFIED' named entity 'SECOND' named entity 'ALTERNATIVE THERAPY' named entity 'REFRACTORY ACUTE GRAFT VERSUS HOST DISEASE' named entity 'TREATMENT FAILURE' named entity 'REASONS' named entity 'FOUND' named entity 'USE' named entity 'PROPOSED' named entity '24 MONTHS' named entity 'RESPONSE TO' named entity 'ENDPOINTS' named entity 'LOW RISK' named entity 'OFFERED' named entity 'DRUGS' named entity 'GRADE III' named entity 'RETROSPECTIVE' named entity 'DIFFERENT' named entity 'STEROID' named entity 'GROUPS' named entity 'NON-' named entity 'MAIN' named entity 'UNKNOWN' named entity 'COMPOSITE ENDPOINT' named entity 'OVERALL SURVIVAL' named entity 'ADDITIONAL' named entity 'SUPERIOR' covid:arg/3e768aaea958fcd6f1453fc0ac7ad6e4a982adad named entity 'DAY 7' named entity 'ALIVE' named entity 'RESPONSE' named entity 'ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION' named entity 'HIGHER' named entity 'THESE' named entity 'CONSECUTIVE' named entity 'MAJORITY' named entity 'INFLIXIMAB' named entity 'GUIDELINES ' named entity '2860' named entity 'LINE' named entity 'AGVHD' named entity 'FAIL' named entity 'EARLY' named entity 'EVALUATION' named entity 'IMMUNOSUPPRESSIVE' named entity 'TO RESPOND' named entity 'UNCONTROLLED' named entity 'HIGH' named entity 'TREATED WITH' named entity 'FAILURE' named entity 'ASSESSED' named entity 'DEATH' named entity 'TREATMENT' named entity 'DAY' named entity 'SECOND' named entity 'LINE' named entity 'SMALL' named entity 'STUDIES' named entity 'EVALUATED' named entity 'MONTHS' named entity 'RECENTLY' named entity 'PROBABILITY' named entity 'HAVE' named entity 'TREATMENT' named entity 'INFLIXIMAB' named entity 'RESPONSE'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software